News Feed

A new study suggests that when cancer treatment is given may be just as important as what treatment is used. Researchers found that patients with advanced non-small cell lung cancer who received immunochemotherapy before 3:00 pm had longer overall and progression-free survival than those treated later in the day. The findings support the growing field of cancer chronotherapy, which aligns treatment with the body's natural circadian rhythm to improve effectiveness and reduce side effects. Although the results are promising, experts emphasize that larger clinical trials are needed before treatment timing becomes a standard part of personalized cancer care.

Scientists have identified a new factor that may explain why multiple sclerosis (MS) progresses more rapidly in some people than others. Researchers found large numbers of “foamy” immune cells in the brains of patients with severe MS. These cells become overloaded with fat droplets after engulfing damaged myelin, the protective coating around nerve fibers. Instead of supporting repair, the fat-filled cells appear to trigger chronic inflammation and further nerve damage, potentially accelerating disease progression. The findings offer new insight into MS biology and highlight these immune cells as a promising target for future therapies aimed at slowing or preventing worsening of the disease.

Scientists have discovered a promising new strategy to fight pancreatic cancer using experimental compounds known as PCAIs. In laboratory studies, a leading PCAI compound blocked more than 90% of cancer cell migration, suggesting it could help prevent tumor spread. Instead of shutting down cancer-promoting signals, the treatment took an unusual approach by hyperactivating key cellular pathways, pushing cancer cells beyond their limits and triggering self-destruction. This innovative mechanism could offer a new way to target one of the most aggressive and treatment-resistant cancers. While the results are highly encouraging, further preclinical and clinical studies are needed to confirm the therapy's safety and effectiveness.

Creatine, a popular supplement known for improving muscle strength and athletic performance, may also have potential as a treatment for depression. A recent review analyzed five randomized clinical trials involving 238 participants to evaluate its effects on mental health. While two studies involving women with major depressive disorder found that creatine enhanced the benefits of standard antidepressant treatment, three other trials showed no significant improvement. Researchers believe creatine may support brain function by increasing cellular energy, but the current evidence remains mixed. Larger, well-designed clinical trials are needed before creatine can be recommended as a routine treatment for depression.

Researchers have identified a potential mechanism that may explain how Alzheimer’s disease spreads through the brain. The study suggests that a common brain protein may transport toxic Tau proteins from damaged neurons to healthy ones, allowing the disease to progressively affect new brain regions. By blocking these harmful protein-containing packages before they enter healthy cells, scientists believe it may be possible to slow or even halt the progression of Alzheimer's. While the findings are still in the research stage and require further validation, they offer a promising new target for developing future treatments aimed at delaying disease progression rather than simply managing symptoms.

Researchers have identified how individual brain cells work together to produce human speech by combining single-cell brain recordings with artificial intelligence. Using data from epilepsy patients with implanted microelectrode arrays, scientists discovered that specific neurons process different aspects of language—from the meaning of words to sentence structure and context. Remarkably, brain activity recorded just before speaking accurately predicted the words participants were about to say. These findings provide the most detailed view yet of how the brain encodes language and could pave the way for advanced brain-computer interfaces that convert neural activity into speech, offering new hope for people with paralysis or communication disorders.

A groundbreaking first-in-human clinical trial has shown promising results for a new treatment targeting retinitis pigmentosa, a leading cause of inherited blindness. Researchers found that a photoswitch molecule injected into the eye reactivated damaged retinal cells, allowing them to respond to light even after normal light-sensing cells were lost. The treatment was well tolerated, with no serious side effects, and some participants experienced improved light perception and better performance in visual tasks. Unlike gene therapies, this approach could work across multiple forms of retinal degeneration without genetic modification. While the findings are preliminary, a larger Phase 2 trial is already underway to evaluate its effectiveness.

Scientists have developed a promising vitamin B12–based compound that could improve treatment for glioblastoma, one of the deadliest forms of brain cancer. In preclinical animal studies, the compound successfully crossed the blood-brain barrier and selectively accumulated inside glioblastoma tumors. It then released sustained levels of nitric oxide directly into cancer cells, helping to slow tumor growth. When combined with existing glioblastoma therapies, the treatment showed a powerful synergistic effect, significantly boosting anti-tumor activity compared to standard treatments alone. Although these findings are still limited to animal studies, they highlight a potential new strategy for delivering targeted therapies to hard-to-treat brain cancers.

A new review suggests that gut microbes play a much larger role in hormone-driven cancers than previously thought. Scientists found that the gut microbiome can influence estrogen levels by producing hormone-like compounds, regulating inflammation, and modifying hormone metabolism. These interactions may affect the development of estrogen-related cancers such as breast and endometrial cancer. Researchers are also exploring microbiome-based therapies, including probiotics, prebiotics, live biotherapeutics, and fecal microbiota transplantation, as potential treatment strategies. However, current evidence is largely based on laboratory and observational studies. Larger clinical trials are needed before these approaches can become part of routine cancer prevention or personalized treatment.

A quick 13-second eye test could help doctors predict whether patients with severe brain injuries are likely to regain consciousness. Researchers found that a little-known part of the pupil's response to light, called the late light-off response (LOR), was linked to improvements in consciousness seven days later. In contrast, standard ICU pupil tests failed to predict recovery. The study analyzed 250 patients with traumatic and non-traumatic brain injuries and suggests that this simple bedside test may reveal the brain's recovery potential before clinical signs appear. Although larger studies are still needed, this promising approach could improve patient monitoring and guide treatment decisions in intensive care units.